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Dr G. Patrick Clagett (Dallas, Tex). Have you used platelet-
imaging studies to document the creation of a nonthrombogenic
surface and, thereby, prove indirectly that there are viable endo-
thelial cells on the prosthetic surface?
Dr Peter Zilla.We have done a preclinical study in primates in
the mid-’80s. What it clearly demonstrated was a nonthrombo-
genic surface. However, in the beginning, you see quite a lot of
inflammatory cells on top of the in vitro-lined endothelium, which
after 4 weeks have completely disappeared.
Dr Rajabrata Sarkar (San Francisco, Calif): Many groups
have tried for years to get endothelium to grow on PTFE [poly-
tetrafluoroethylene] grafts. And now we know that stem cells are
always attracted to sites of vascular inflammation. Andmy question
for you is: Do you think that the cells that you find at explantation
are actually the endothelial cells that you seeded, or have you just,
with the fibrin glue, created a better landing site for these circulat-
ing endothelial-like stem cells?
DrZilla.This is a very good point. I would go one step further
and expand it beyond the endothelial cells. The fact that we found
actin-positive cells in the subendothelial layers and, in some areas,
even tissue that resembles a vascular wall, makes one wonder how
these cells got there. So far, we could not answer whether the
originally transplanted endothelial cells transdifferentiated into
actin-positive cells or whether the graft surfaces were homing sites
for circulating cells.
Dr Sarkar. And my follow-up question is: How do you
confirm that these are actually endothelial cells? Because exposed
smooth muscle cells, when exposed to laminar flow, will line up in
an endothelial cell-like monolayer.
Dr Zilla. I showed a series of immunofluorescence pictures.
We didn’t only use factor VIII but also CD31 and transmission
electron microscopy. The surface cells were all very clearly endo-
thelial cells.
Dr Alexander Clowes (Seattle, Wash). I am intrigued by your
morphology. Have you had the opportunity to do longitudinal
studies using duplex scanning or MR [magnetic resonance] to findDr Zilla. It would have been great had we also done such a
clinical study in a tertiary hospital, but this study was done in a
community hospital with the purpose of demonstrating that the
method can really be done everywhere as a clinical routine service
without academic sophistication. Therefore, the answer is no, we
don’t have this information, but the fact that the 1-year follow-up
hardly showed any surface irregularities indicates that the process is
slow and scarce.
Dr Kai Balzer (Dusseldorf, Germany). Three questions. First
one, the hope to make the layer of endothelium was to inhibit
myointimal hyperplasia. The pictures you showed kind of ques-
tioned that from the few specimens you obtained. The second
question, have you ever tried—because from our experience, en-
dothelial cells that you gain from veins sometimes lose the possi-
bility to proliferate after several cell cycles—have you ever tried
endothelial progenitor cells from the bone marrow? And the third
question would be, have you ever tried labeling your cells that
maybe even after 1 year you could see if those cells that you
implanted were the ones still on the graft.
Dr Zilla. Let me start with the first question. The fact that in
some areas we end up with a double layer where the actin-positive
subendothelial cells show signs of a contractile phenotype indicates
that the cells on the graft surface may attempt to emulate some-
thing physiological. Why other areas have an endothelium lying on
naked blank PTFE after 63 months with inflammatory cells stuffed
in between, I can’t explain.
With regards to labeling: Remember, Manfred Deutsch and I
are veterans in that field, so even the last leg of the academic part of
the study was performed more than 15 years ago, when methods
such as adeno-associated viruses to deliver green fluorescent pro-
tein were not available yet. But I would love to see a follow-up on
that question done by younger colleagues.
Dr Balzer. And progenitor cells?
Dr Zilla. The same applies here: based on the encouragement
of the long-term clinical results, a new round of academic interest
seems justified.
